| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 324,35 | 327,60 | 22:52 | |
| 323,55 | 325,60 | 22:00 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 349,00 | 10 | |||
| 338,10 | 1 | |||
| 325,60 | 25 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/amg.htm [/URL] | ||||
| 25 | 323,55 | |||
| 1.053 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.078 | 0,033 | 36 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:25:15 | 329,20 | 8 |
| 15:14:40 | 328,85 | 14 |
| 15:14:40 | 328,90 | 54 |
| 14:44:35 | 328,40 | 1 |
| 14:44:35 | 328,45 | 8 |
| 14:44:35 | 328,45 | 54 |
| 12:06:15 | 328,50 | 20 |
| 10:00:27 | 330,65 | 3 |
| 09:40:35 | 328,50 | 16 |
| 09:40:35 | 328,90 | 4 |
| 09:30:25 | 328,95 | 6 |
| 09:30:25 | 328,95 | 10 |
| 09:30:25 | 328,95 | 8 |
| 09:27:32 | 327,55 | 10 |
| 09:27:32 | 327,60 | 4 |
| 09:04:40 | 328,55 | 130 |
| Tagesumsatz Xetra | -6,95 -2,11 % | 528 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AMGEN Aktie jetzt für 0€ handeln | |||||
| 16:06 | Amgen EVP Sold $20.77M In Company Stock | 3 | Benzinga.com | ||
| Mo | AAPL, AA, BKR, and AMGN are among the top stocks for momentum, says Oppenheimer | 11 | Seeking Alpha | ||
| Mi | Is Amgen Stock Outperforming the Dow? | 13 | Barchart.com | ||
| 24.02. | NSE - AMGEN INC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
| 23.02. | If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today | 7 | Benzinga.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:06 | Prime Medicine, Inc.: Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates | GlobeNewswire (Europe) | -- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for... ► Artikel lesen | |
| 14:21 | EQS-Media: REPLOID Group AG: Feierliche Eröffnung der ersten landwirtschaftlichen ReFarmUnit | EQS Group (DE) | EQS-Media / 03.03.2026 / 14:19 CET/CEST
PRESSEMITTEILUNG
REPLOID Group AG: Feierliche Eröffnung der ersten landwirtschaftlichen ReFarmUnit
Wels, 3. März 2026 - Gestern fand die feierliche... ► Artikel lesen | |
| 14:06 | Arcutis Biotherapeutics, Inc.: Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis | GlobeNewswire (Europe) | Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein... ► Artikel lesen | |
| 18:36 | Oncodesign Precision Medicine Receives Support from The Michael J. Fox Foundation to Advance Development of LRRK2 Inhibitor OPM-201 for Parkinson's Disease | Business Wire | The grant will support the preparation of clinical Drug Product for Phase 1b and start of Phase 2 in people with Parkinson's disease and the execution of long-term toxicology study including... ► Artikel lesen | |
| 15:27 | XFRA 0TB: WIEDERAUFNAHME/RESUMPTION | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |